Damora Therapeutics, Inc.
Damora Therapeutics, Inc. (DMRA): 6 pipeline candidates · ~78 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
77.7 months
D/E 0.05 · 0% dilution
Lead: Phase 2
6 candidates
N/A
0 buys · 3 sells (180d)
A transparent, data-derived signal for Damora Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.3B
Cash
$532.9M
Quarterly Burn
$20.6M
Runway
77.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
60
Total value held
$959.8M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 9,045,481 | $234.3M |
| perceptive advisors llc | 2,446,000 | $63.4M |
| fcpm iii services b.v. | 2,441,000 | $63.2M |
| ra capital management, l.p. | 2,399,310 | $62.1M |
| janus henderson group plc | 2,362,696 | $61.4M |
| viking global investors lp | 2,311,082 | $59.9M |
| commodore capital lp | 1,939,000 | $50.2M |
| cormorant asset management, lp | 1,525,000 | $39.5M |
| balyasny asset management l.p. | 1,448,000 | $37.5M |
| a16z capital management, l.l.c. | 1,236,157 | $32.0M |
Showing top 10 of 60 institutional holders of Damora Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Damora Therapeutics, Inc.'s pipeline?
Damora Therapeutics, Inc. (DMRA) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Damora Therapeutics, Inc.'s lead drug candidate?
Damora Therapeutics, Inc.'s most advanced tracked candidate is dmr-001 (Preclinical) for Essential thrombocythemia (ET) and myelofibrosis (MF).
What is Damora Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Damora Therapeutics, Inc. has approximately 77.7 months of cash runway.
What is Damora Therapeutics, Inc.'s market capitalization?
Damora Therapeutics, Inc.'s market capitalization is approximately $1.3B.
Who is the CEO of Damora Therapeutics, Inc.?
Ms. Jennifer A. Jarrett M.B.A. is the chief executive officer of Damora Therapeutics, Inc. (DMRA).
Get the full picture on Damora Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.